Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: EHP
Latest Price: 355.00p  (0,00%)
52-week High: 400.00p
52-week Low: 347.50p
Market Cap: 31.40M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Epistem Holdings Plc
www.epistem.co.uk

Epistem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. Epistem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

Full Epistem Holdings Plc profile here
Pdf

Stem Cell specialist Epistem says trading strong, expects maiden full year profit

31st Jul 2009, 11:07 am Stem Cell specialist Epistem says trading strong, expects maiden full year profit

Adult epithelial stem cell specialist, Epistem plc (AIM: EHP) confirmed yesterday that it would post a maiden profit after tax for the full year ending 30 June 2009, thanks to “strong” trading and a tax credit from the prior year.


Shares in Epistem were little moved on the announcement, not entirely unsurprising when looking at the strong appreciation in its share price over the past few months.  Clearly the market was confident that the company would hit its numbers, and the market is not often wrong.


Epistem’s recent share price performance places is amongst the best performing stocks in the biotechnology and pharmaceutical sector, in spite of two of its largest shareholders, Helium Special Situations Fund and Calculus Capital, both taking advantage of recent gains to trim their holdings to 9.4% and 13.99% respectively.


The company’s business model is based around leveraging its intellectual property and the expertise in stem cell research. The company’s three divisions include: Novel Therapies, which looks to find preclinical leads for new drugs; Contract Research, which looks at the preclinical efficacy of third party new drug compounds; and Biomarkers, which work with both preclinical and clinical stage drugs in development.

Both Daniel Stewart and Piper Jaffray (Nomad and House Broker) have a ‘buy’ stance on Epistem. Daniel Steward if forecasting full year (June 30 2010) profit before tax of £0.8 million on revenues of £5.3 million.  Piper Jaffray is slightly more bullish, anticipating FY 2010 profit before tax of £0.9 million on revenues of £5.5 million.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.